Triple-targeted therapy with CDK4/6 inhibitor for HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of three anti-HER2 drugs plus a CDK4/6 inhibitor before surgery for women with a type of breast cancer that is both HER2-positive and ER-positive. It aims to see if this treatment can shrink tumors more effectively before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- Your breast cancer is stage II or III and has not spread to other parts of the body.
- Your tumor is HER2-positive and estrogen receptor (ER)-positive (ER at least 10%).
- You are postmenopausal, or if premenopausal you are willing to have your ovaries suppressed or removed.
- You have good overall health status (ECOG score 0 or 1) and normal heart, blood, and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stronger treatment (a CDK4/6 inhibitor) combined with less chemotherapy for early-stage breast cancer that is positive for hormone receptors and HER2. It aims to see if this approach works well while reducing side effects from chemo.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests whether a combination of targeted therapies and hormone therapy can shrink triple-positive breast cancer before surgery. It is for women with stage II or III breast cancer that has not yet been treated.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.